South Africa Cell And Gene Therapy Cdmo Market Size & Outlook
Related Markets
South Africa cell and gene therapy cdmo market highlights
- The South Africa cell and gene therapy cdmo market generated a revenue of USD 19.3 million in 2024 and is expected to reach USD 64.7 million by 2033.
- The South Africa market is expected to grow at a CAGR of 14.4% from 2025 to 2033.
- In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
- Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
| Market revenue in 2024 | USD 19.3 million |
| Market revenue in 2033 | USD 64.7 million |
| Growth rate | 14.4% (CAGR from 2025 to 2033) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.4% of the global cell and gene therapy cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Middle East & Africa, Saudi Arabia cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2033.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 56.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Cytiva | View profile | 10001+ | Marlborough, Massachusetts, United States, North America | https://www.cytivalifesciences.com/en/us |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | https://www.rentschler-biopharma.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| AGC Inc | View profile | 61671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | https://www.agc.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| OmniAb Inc | View profile | 106 | 5980 Horton Street, Suite 600, Emeryville, CA, United States, 94608 | https://www.omniab.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Samsung Electronics Co Ltd | View profile | 124804 | 129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742 | https://www.samsung.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
South Africa cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 75.13% in 2024. Horizon Databook has segmented the South Africa cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
South Africa cell & gene therapy CDMO market is expected to witness considerable growth due to the increasing demand for biologics, rising initiatives by biopharmaceutical companies, and the presence of a diverse population in the country.
In addition, the availability, affordability, accessibility, and quality of generic products & biologics in South Africa are anticipated to fuel market growth during the forecast period. However, slow economic growth & development of the healthcare system, imports of APIs, and potentially rising prices of key medicines in the country are anticipated to impede market growth in the coming decade.
Furthermore, in the country, the research industry complies with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) & FDA standards. The diverse population & cost-effective trials are some of the primary drivers of the cell and gene therapy CDMO market.
Reasons to subscribe to South Africa cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Africa cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into South Africa cell and gene therapy cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
South Africa cell and gene therapy cdmo market size, by phase, 2021-2033 (US$M)
South Africa Cell And Gene Therapy CDMO Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
